Special Issue

Diagnostic Biomarkers in Cancers Study

Message from the Guest Editors

This Special Issue focuses on recent advancements and challenges in identifying and utilizing diagnostic biomarkers for cancer. Biomarkers—including genetic, epigenetic, proteomic, and metabolomic markers—are crucial for early detection, patient stratification, and personalized medicine. The collected research highlights the discovery and validation of novel biomarkers for various cancers and cancer-related diseases. Key topics include the clinical translation of biomarkers and addressing challenges related to regulation, standardization, and cost-effectiveness. Moreover, the issue explores the role of biomarkers in personalized medicine, offering insights into patient-specific treatment responses and therapeutic strategies. Overall, this Special Issue provides a comprehensive understanding of how advancements in biomarkers can revolutionize disease diagnostics, enhance patient outcomes, and propel the field of precision oncology forward.

Guest Editors

Dr. Zejuan Li

Institute for Academic Medicine, Houston Methodist Research Institute, Weill Cornell Medical College, Houston Methodist Hospital, Houston, TX 77030, USA

Dr. Xin Yi

1. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX 77030, USA
2. Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065, USA

Deadline for manuscript submissions

31 October 2025

MDPI

Cancers

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:
free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)